A phase II trial of niraparib in combination with bevacizumab patients with first-line ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 16 May 2018
At a glance
- Drugs Bevacizumab (Primary) ; Niraparib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms OVARIO
- 16 May 2018 According to a TESARO media release, data from this trial will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a TESARO Inc. media release, this trial is expected to initiate by the end of 2017.